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Abstract
Background: Luteolin, a plant derived flavonoid, exerts a variety of pharmacological activities and anti-oxidant
properties associated with its capacity to scavenge oxygen and nitrogen species. Luteolin also shows potent anti-
inflammatory activities by inhibiting nuclear factor kappa B (NFkB) signaling in immune cells. To better understand
the immuno-modulatory effects of this important flavonoid, we performed a genome-wide expression analysis in
pro-inflammatory challenged microglia treated with luteolin and conducted a phenotypic and functional
characterization.
Methods: Resting and LPS-activated BV-2 microglia were treated with luteolin in various concentrations and mRNA
levels of pro-inflammatory markers were determined. DNA microarray experiments and bioinformatic data mining
were performed to capture global transcriptomic changes following luteolin stimulation of microglia. Extensive
qRT-PCR analyses were carried out for an independent confirmation of newly identified luteolin-regulated
transcripts. The activation state of luteolin-treated microglia was assessed by morphological characterization.
Microglia-mediated neurotoxicity was assessed by quantifying secreted nitric oxide levels and apoptosis of 661W
photoreceptors cultured in microglia-conditioned medium.
Results: Luteolin dose-dependently suppressed pro-inflammatory marker expression in LPS-activated microglia and
triggered global changes in the microglial transcriptome with more than 50 differentially expressed transcripts. Pro-
inflammatory and pro-apoptotic gene expression was effectively blocked by luteolin. In contrast, mRNA levels of
genes related to anti-oxidant metabolism, phagocytic uptake, ramification, and chemotaxis were significantly
induced. Luteolin treatment had a major effect on microglial morphology leading to ramification of formerly
amoeboid cells associated with the formation of long filopodia. When co-incubated with luteolin, LPS-activated
microglia showed strongly reduced NO secretion and significantly decreased neurotoxicity on 661W photoreceptor
cultures.
Conclusions: Our findings confirm the inhibitory effects of luteolin on pro-inflammatory cytokine expression in
microglia. Moreover, our transcriptomic data suggest that this flavonoid is a potent modulator of microglial
activation and affects several signaling pathways leading to a unique phenotype with anti-inflammatory, anti-
oxidative, and neuroprotective characteristics. With the identification of several novel luteolin-regulated genes, our
findings provide a molecular basis to understand the versatile effects of luteolin on microglial homeostasis. The
data also suggest that luteolin could be a promising candidate to develop immuno-modulatory and
neuroprotective therapies for the treatment of neurodegenerative disorders.
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Microglia, the resident macrophages of the nervous sys-
tem, have important roles in immune regulation [1,2]
and neuronal homeostasis [3,4]. Microglia belong to the
mononuclear phagocyte system but their special locali-
zation in the fragile neuronal environment and their
morphological features clearly distinguish them from
other peripheral macrophages [5]. Ramified microglia
perform a very active and continous surveillance func-
tion with their long protrusions [6,7]. They receive per-
manent tonic inhibitory inputs from neurons to prevent
microglial neurotoxicity [8,9]. Loss of microglia-neuron
cross-talk [10], local danger signals such as extracellular
ATP [11], or neurotransmitter gradients [12] rapidly
lead to a functional transformation of ramified microglia
with a variety of effector functions.
Microglia activation is a protective mechanism regu-
lating tissue repair and recovery in the early phase of
neurodegeneration [4]. However, excessive or sustained
activation of microglia often contributes to acute and
chronic neuro-inflammatory responses in the brain and
the retina [2]. Activated microglia in the vicinity of
degenerating neurons have been identified in a broad
spectrum of neurodegenerative disorders including Alz-
heimer’s disease [13], Parkinson’s disease [14], amyo-
trophic lateral sclerosis [15], multiple sclerosis [16], and
inherited photoreceptor dystrophies [17,18].
Macrophage heterogeneity and plasticity is very large
and the set of marker combinations and sub-populations
is essentially infinite [19]. To define a simplified concep-
tual framework, classification into polarized functional
categories, called M1 and M2 macrophages has been
proposed [20,21]. M1 or “classically activated” macro-
phages produce high levels of oxidative metabolites and
pro-inflammatory cytokines but also cause damage to
h e a l t h yt i s s u ea ss i d ee f f e c t[ 2 2 ] .M 2o r“alternatively
activated” macrophages promote tissue remodeling and
generally suppress destructive immune reactions. Infor-
mations on microglial subsets in the nervous system are
relatively scarce compared to other tissue macrophages.
Nevertheless, recent findings from in vitro cultures of
the murine microglial cell line MMGT12 [23] and hip-
pocampal microglia from the PS1xAPP Alzheimer’s
mouse model [24] implicate that microglia have the abil-
ity to differentiate into M1 and M2 polarized pheno-
types. A co-existence of neurotoxic M1 microglia and
regenerative M2 microglia has been recently documen-
ted in the injured mouse spinal cord [25]. Microarray-
based quantitation of M1 and M2 markers as well as
functional tests on axonal regrowth after injury demon-
strated that a transient anti-inflammatory and neuropro-
tective M2 response was rapidly overwhelmed by a
neurotoxic M1 microglial response [25]. A similar but
age-dependent switch from alternative to classical acti-
vation was shown in PS1xAPP Alzheimer’s mice [24],
indicating a common phenomenon in neurodegenerative
disorders. Compounds that induce the switch of micro-
glia from inflammatory M1 type to anti-inflammatory
M2 type could therefore be a potential therapeutic agent
to attenuate neuronal inflammation and boost neuronal
recovery [26].
Several anti-inflammatory drugs have been shown to
diminish neuroinflammation, but only a few direct func-
tional effects on microglial activity have been elucidated
[27]. Among the naturally occuring immuno-modula-
tors, the flavonoid luteolin (3’,4’,5,7-tetrahydroxyfla-
vone), abundant in parsley, green pepper, celery, perilla
leaf, and chamomile tea, exerts prominent anti-inflam-
matory and anti-oxidant activities [28]. Luteolin sup-
pressed pro-inflammatory cytokine production in
macrophages by blocking nuclear factor kappa B (NFkB)
and activator protein 1 (AP1) signaling pathways [29]
and inhibited the production of nitric oxide [30] and
pro-inflammatory eicosanoids [31]. Luteolin also
diminshed the release of Tnf and superoxide anions in
LPS or interferon-g treated microglial cell cultures
[32,33] and reduced the LPS-induced Il6 production in
brain microglia in vivo [34].
Although the inhibitory function of luteolin on NFkB
and a few selected cytokines is well documented in
macrophages, a genome-wide search for further molecu-
lar targets in microglia has not yet been published.
Furthermore, the immuno-modulatory effects of luteolin
related to the stimulation of distinct functional micro-
glial phenotypes has not been investigated before.
Therefore, this study investigated the global transcrip-
tomic effects of luteolin at near physiological concentra-
tions [35] alone or in combination with LPS in pure
BV-2 microglial cultures. We further validated the luteo-
lin-regulated expression of novel pro- and anti-inflamm-
tory microglial transcripts, analyzed microglial
morphology, and studied the consequences of microglia-
conditioned media for photoreceptor viability.
Methods
Reagents
Luteolin (3’,4’,5,7-tetrahydroxyflavone) and E. coli 0111:
B4 lipopolysaccharide were purchased from Sigma
Aldrich (Steinheim, Germany). Luteolin was dissolved in
DMSO and added in concentrations that did not exceed
0.05% of the total volume in any of the cell culture
experiments.
Animals
C57BL/6 mice were purchased from Charles River
Laboratories. Mice were kept in an air-conditioned bar-
rier environment at constant temperature of 20-22°C on
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and water. The health of the animals was regularly mon-
itored, and all procedures were approved by the Univer-
sity of Regensburg animal rights committee and
complied with the German Law on Animal Protection
and the Institute for Laboratory Animal Research Guide
for the Care and Use of Laboratory Animals, 1999.
Cell culture
Brain microglia were isolated and cultured as described
earlier [36]. BV-2 microglia-like cells were provided by
Professor Ralph Lucius (Clinic of Neurology, Christian
Albrechts University, Kiel, Germany). BV-2 cells were
cultured in RPMI/5% FCS supplemented with 2 mM L-
Glutamine and 195 nM b-mercaptoethanol. Primary
brain microglia or BV-2 cells were stimulated with 10
ng/ml or 50 ng/ml LPS and various concentrations of
luteolin for 24 h. 661W photoreceptor-like cells were a
gift from Prof. Muayyad Al-Ubaidi (University of Illinois,
Chicago, IL) and the culture conditions have been
described elsewhere [36].
Phalloidin staining
BV-2 cells were plated overnight on coverslips, fixed
with 3.7% paraformaldehyde for 10 min at 37°C, per-
meabilized with 0.2% Triton X-100 for 5 min, blocked
with 5% non-fat milk, 0.2% Triton X-100, and stained
with DAPI for 10 min at room temperature (0.1 μg/ml
in PBS, 4’,6-diamidino-2-phenylindol, Molecular Probes).
Filamentous actin was stained by addition of 1.5 μM
TRITC-conjugated phalloidin (Sigma). The coverslips
were mounted on microscopic glass slides and viewed
with a Axioskop 2 fluorescence microscope equipped
with an Eclipse digital analyzer (Carl Zeiss).
NO measurement
NO concentrations were determined by measuring the
amount of nitrite secreted by BV-2 cells into the culture
medium using the Griess reagent system (Promega). 50
μl cell culture supernatant was collected and an equal
volume of Griess reagent was added to each well. After
incubation for 15 min at room temperature, the absor-
bance was read at 540 nm on a BMG FluoStar Optima
plate reader (Labtech, Offenburg, Germany). The con-
centration of nitrite for each sample was calculated
from a sodium nitrite standard curve.
Apoptosis assay
Apoptotic cell death of 661W cells was determined with
the Caspase-Glo® 3/7 Assay (Promega). Cells were lysed
and incubated with a luminogenic caspase-3/7 substrate,
which contains the tetrapeptide sequence DEVD. Lumi-
nescence was then generated by addition of recombinant
luciferase and was proportional to the amount of cas-
pase activity present. The luminescent signal was read
on a BMG FluoStar Optima plate reader (Labtech,
Offenburg, Germany). A blank reaction was used to
measure background luminescence associated with the
cell culture system and Caspase-Glo® 3/7 Reagent. The
value for the blank reaction was subtracted from all
experimental values. Negative control reactions were
performed to determine the basal caspase activity of
661W cells.
RNA isolation and reverse transcription
Total RNA was extracted from cultured microglia
according to the manufacturer’s instructions using the
RNeasy Protect Mini Kit (Qiagen, Hilden, Germany).
Purity and integrity of the RNA was assessed on the
Agilent 2100 bioanalyzer with the RNA 6000 Nano Lab-
Chip® reagent set (Agilent Technologies, Büblingen, Ger-
many). The RNA was quantified spectrophotometrically
and then stored at -80°C. First-strand cDNA synthesis
was performed with RevertAid™ HM i n u sF i r s tS t r a n d
cDNA Synthesis Kit (Fermentas, St. Leon-Rot,
Germany).
DNA microarray analysis
Triplicate microarrays were carried out with three inde-
pendent RNAs from non-stimulated BV-2 microglia or
cultures treated for 24 h with 50 μM luteolin, 50 ng/ml
LPS, or 50 μM LPS + 50 ng/ml LPS, respectively. Gen-
eration of double-stranded cDNA, preparation and
labeling of cRNA, hybridization to Affymetrix 430 2.0
mouse genome arrays, washing, and scanning were per-
formed according to the Affymetrix standard protocol.
Minimum information about a microarray experiment
(MIAME) criteria were met [37]. The microarray data-
sets of this study are publicly available at the National
Center for Biotechnology Information Gene Expression
Omnibus http://www.ncbi.nlm.nih.gov/geo/ as series
record GSE18740.
Bioinformatic data analysis
The Affymetrix Expression Console Software Version
1.0 was used to create summarized expression values
(CHP-files) from 3’ expression array feature intensities
(CEL-files) using the Robust Multichip Analysis (RMA)
algorithm. Integrative analysis of genome-wide expres-
sion activities from BV-2 cells was performed with the
Gene Expression Dynamics Inspector (GEDI), a Matlab
(Mathworks, Natick, MA) freeware program which uses
self-organizing maps (SOMs) to translate high-dimen-
sional data into a 2D mosaic [38]. Each tile of the
mosaic represents an individual SOM cluster and is
color-coded to represent high or low expression of the
cluster’s genes, thus identifying the underlying pattern.
Differentially regulated transcrips in 24 h luteolin sti-
mulated versus non-treated and luteolin + LPS versus
LPS-treated BV-2 cells, respectively, were retrieved with
the Genomatix ChipInspector program (Genomatix
Software GmbH, Munich, Germany), applying the Sig-
nificance Analysis of Microarray (SAM) algorithm using
a false-discovery rate of 0.1% and a minimum coverage
of 3 independent probes.
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using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) [39] and the Bibliosphere
pathway edition (Genomatix).
Quantitative real-time RT-PCR
Amplifications of 50 ng cDNA were performed with an
ABI7900HT machine (Applied Biosystems) in triplicates
in 10 μl reaction mixtures containing 1 × TaqMan Uni-
versal PCR Master Mix (Applied Biosystems), 200 nM
of primers and 0.25 μl dual-labeled probe (Roche Probe-
Library). The reaction parameters were as follows: 2-
min 50°C hold, 30-min 60°C hold, and 5-min 95°C hold,
followed by 45 cycles of 20-s 94°C melt and 1-min 60°C
anneal/extension. Measurements were performed in tri-
plicate. Results were analyzed with an ABI sequence
detector software version 2.3 using the ΔΔCt method
for relative quantitation. Primer sequences and Roche
Library Probe numbers are listed in Table 1.
Statistical analysis
Statistical analysis were performed on ΔΔCt data using
analysis of variance with a two-sample Student’stt e s t
(P < 0.05) unless otherwise indicated. Quantitative data
are expressed as mean ± SEM. The levels of gene
expression in treated BV-2 cells are shown relative to
control cells.
Results
Effects of luteolin on selected pro-inflammatory markers
As a basis to study the genome-wide transcriptional effects
of luteolin on activated microglia and to validate our cell
culture system, we initially performed a dose-response
curve for luteolin. Four pro-inflammatory microglia
Table 1 Primer pairs and Roche library probes for real time qRT-PCR validation
Gene F-Primer (5’-3’) R-Primer (5’-3’) Roche Library Probe
AA467197 aaatggtggatcctactcaacc gttgccctccggactttt 17
Blvrb tcctcggagttctcagcttt gcaccgtcacctcataacct 81
C3 accttacctcggcaagtttct ttgtagagctgctggtcagg 76
CD36 ttgaaaagtctcggacattgag tcagatccgaacacagcgta 6
CD83 gctctcctatgcagtgtcctg ggatcgtcagggaataggc 2
Cfb ctcgaacctgcagatccac tcaaagtcctgcggtcgt 1
Cst7 atgtcagcaaagccctggta ggtcttcctgcatgtagttcg 67
Cxcl10 gctgccgtcattttctgc tctcactggcccgtcatc 3
Ddit3 ccaccacacctgaaagcag tcctcataccaggcttcca 33
Gbp2 tgtagaccaaaagttccagacaga gataaaggcatctcgcttgg 62
Gbp3 aagattgagctgggctacca gaaactcttgagaacctcttttgc 73
Gclm tggagcagctgtatcagtgg caaaggcagtcaaatctggtg 18
Gusb gtgggcattgtgctacctg atttttgtcccggcgaac 25
Hmox1 ctgctagcctggtgcaaga ccaacaggaagctgagagtga 25
Hp ccctgggagctgttgtca ctttgggcagctgtcatctt 15
Hprt1 tcctcctcagaccgctttt cctggttcatcatcgctaatc 95
Ifi44 ctgattacaaaagaagacatgacagac aggcaaaaccaaagactcca 78
Ifitm3 aacatgcccagagaggtgtc accatcttccgatccctagac 84
Ifitm6 ccggatcacattacctggtc catgtcgcccaccatctt 27
IL-6 gatggatgctaccaaactggat ccaggtagctatggtactccaga 6
iNos ctttgccacggacgagac tcattgtactctgagggctga 13
Irf7 cttcagcactttcttccgaga tgtagtgtggtgacccttgc 25
Kdr cagtggtactggcagctagaag acaagcatacgggcttgttt 68
Lcn2 atgtcacctccatcctggtc cctgtgcatatttcccagagt 1
Lpcat1 aatgtgaggcgtgtcatgg ggcagtcctcaaatgtatagtcg 81
Marco cagagggagagcacttagcag gccccgacaattcacatt 20
Mpeg1 cacagtgagcctgcacttaca gcgctttcccaatagcttta 69
Nupr1-F gatggaatcctggatgaatatga gtccgacctttccgacct 64
Rnf145 catggacttctggcttctcat aataaaaagtgttcccagaacctg 67
Saa3 atgctcgggggaactatgat acagcctctctggcatcg 26
Slpi gtgaatcctgttcccattcg cctgagttttgacgcacctc 69
Srxn1 gctatgccacacagagaccata gtgggaaagctggtgtcct 33
Trib3 gctatcgagccctgcact acatgctggtgggtaggc 98
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induction were selected as positive controls for qRT-PCR
analyses. Interleukin 6 (Il6) is a well known pro-inflamma-
tory cytokine target of luteolin [34], chemokine (C-X-C
motif) ligand 10 (Cxcl10), interferon-regulatory factor 7
(Irf7), and interferon-inducible protein 44 (Ifi44) are LPS-
sensitive genes in microglia [36]. BV-2 microglia were pre-
treated with different concentrations of luteolin (0, 5, 10,
25, and 50 μM) for 1 h and then stimulated with LPS (10
ng/ml and 50 ng/ml) for a further 24 h period. Neither
LPS nor luteolin changed the proliferation rate or cell sur-
vival at the concentration levels applied to the cells (data
not shown). mRNA levels of Il6 (Fig. 1A), Cxcl10 (Fig. 1B),
Irf7 (Fig. 1C), and Ifi44 (Fig. 1D), which were all induced
by 10 ng/ml LPS and further increased by 50 ng/ml LPS,
were dose-dependently reduced by luteolin (Fig. 1A-D).
Luteolin’s effects on the four genes were most prominent
at 50 μM (Fig. 1A-D) and therefore this concentration was
used in all further experiments.
Luteolin triggers global changes in the microglial
transcriptome
Our next goal was to capture and compare the transcrip-
tional profile of non-activated and LPS-activated BV-2
microgli treated each with 50 μM luteolin for 24 h using
Affymetrix Mouse Genome 430 2.0 GeneChips. Twelve
microarray analyses from three independent stimulation
experiments were performed and high stringency criteria
with a minimal signal intensity of 50 fluorescence units
were used. The complete microarray RMA datasets and
all raw data (Affymetrix CEL-files) were stored in the
NCBI GEO repository as record GSE18740. We used the
Gene Expression Dynamics Inspector (GEDI) to deter-
mine the global patterns of gene expression in the four
different conditions, untreated, luteolin-treated, LPS-trea-
ted, and luteolin + LPS-treated microglia. GEDI is based
on self-organizing maps to identify genome-wide tran-
scriptome activity via ‘gestalt’ recognition [38]. GEDI is
sample-oriented rather than gene-oriented, which facili-
tates the identification of genome-wide patterns. Each
mosaic tile in the GEDI map represents a gene group or
cluster that is expressed at similar levels, with blue color
indicating a low level and red corresponding to high
expression. The four GEDI maps clearly show a dynamic
regulation of gene expression in stimulated versus non-
stimulated microglia (Fig. 2). Especially the upper right
positions in the control dataset and more pronounced in
the LPS-treated dataset display an inverse regulation of
the gene clusters following luteolin stimulation (Fig. 2A,
white circles). These results demonstrate that stimulation
with luteolin has a major impact on the global pattern of
gene expression notably in activated microglia and to a
lower extend in resting cells.
Figure 1 Dose-dependent suppression of LPS-induced pro-inflammatory gene expression in BV-2 microglia. BV-2 microglia were treated
with the indicated concentrations of luteolin for 1 h and then stimulated with 10 ng/ml or 50 ng/ml LPS for 24 h. Gene expression levels of (A)
interleukin 6 (Il6), (B) chemokine (C-X-C motif) ligand 10 (Cxcl10), (C) interferon-regulatory factor 7 (Irf7), and (D) interferon-induced gene 44 (Ifi)
were analyzed with real-time qRT-PCR. Expression was normalized to the control gene Gusb and mRNA levels (+/- SEM) are graphed relative to
mock-treated control cells. Results are calculated from three independent experiments performed in triplicate measurements. * p ≤ 0.05, ** p ≤
0.01, and *** p ≤ 0.001 for luteolin + LPS vs. LPS, respectively.
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of Affymetrix microarrays using the Genomatix ChipIn-
spector tool with the Significance Analysis of Microarray
(SAM) algorithm improves detection of regulated tran-
scripts [40]. We therefore used ChipInspector to analyze
our dataset applying a false discovery rate (FDR) of
0.1%, a minimal probe coverage of 3, and a minimum
log2 ratio of 1 (fold change of 2.0). Thereby, 18
significantly regulated genes were identified in luteolin-
treated versus non-treated microglia (Table 2) and 54
differentially expressed genes were detected in luteolin +
LPS versus LPS-stimulated cells (Table 3). Comparison
of the total numer of differentially expressed genes indi-
cated that the effects of luteolin were more pronounced
in LPS-activated BV-2 cells than in resting microglia.
Also, the overall fold change range was higher in the
LPS-treated microglia than in the resting BV-2 cells
when stimulated with luteolin. These finding correlate
with the gene cluster patterns observed in GEDI analysis
and implicate that luteolin is an effective counter-player
of pro-inflammatory microglial activation.
Luteolin regulates important immune pathways and
changes the microglial transcriptional phenotype
Our next aim was to put the newly identified luteolin-
regulated expression patterns into a specific biological
context. We used all differentially expressed genes to
perform a classification into functional categories with
t h eD a t a b a s ef o rA n n o t a t i o n , Visualization, and Inte-
grated Discovery (DAVID). The major enriched func-
tional categories in luteolin-treated resting microglia
were anti-oxidants, phagocytosis,a n danti-inflammation
for up-regulated genes and pro-inflammation and apop-
tosis for down-regulated genes (Fig. 2B, upper part).
These pathways indicate that luteolin stimulated anti-
oxidant and anti-inflammatory transcriptional programs
which could potentially reflect M2 macrophage polariza-
tion. Moreover, basal pro-inflammatory and pro-apopto-
tic gene expression was blocked in non-activated BV-2
microglia. In luteolin + LPS co-treated versus LPS-trea-
ted cells, 11 induced transcripts represented pathways of
lipid metabolism, antigen presentation,a n danti-oxi-
dants (Fig. 2B, bottom left). Interestingly, a large num-
ber of down-regulated genes covered the pathway
categories pro-inflammation, toll-like receptor (TLR) sig-
naling, acute phase response, apoptosis,a n dcomplement
factors (Fig. 2B, bottom right). These results implicate
that luteolin-induced transcriptomic changes promote a
stable anti-inflammatory, anti-oxidant, and anti-apopto-
tic microglial phenotype reminescent of M2 macro-
phages. Our microarray data also identified a significant
number of genes that could not be grouped into larger
immune-related pathways and that have not been pre-
viously connected to microglial activation or flavonoid
stimulation (Tables 2 and 3).
Microarray validation by qRT-PCR confirms novel luteolin-
regulated target genes
To validate a significant portion of the DNA microarray
results, real-time qRT-PCR analyses were carried out
with RNA samples from three independent BV-2 repli-
cate experiments. We focused on representative candi-
dates from different biological pathway which have not
been previously described as flavonoid targets. 22 genes
Figure 2 Luteolin triggers global transcriptomic changes in
non-activated and LPS-activated BV-2 microglia. (A) Comparative
Gene Expression Dynamics Inspector (GEDI) analysis of DNA-
microarray datasets from control BV-2 cells or cells treated with 50
μM luteolin, 50 ng/ml LPS, or 50 μM luteolin + 50 ng/ml LPS. The
white circle denotes the most prominent expression changes in
several corresponding gene clusters. (B) Genomatix ChipInspector
single probe analysis of differentially expressed transcripts in luteolin
versus control-treated cells (top) or luteolin + LPS treated cells
versus LPS stimulated cells. Triplicate Affymetrix Mouse 430 2.0
GeneChips were analyzed with a false-discovery-rate (FDR) <0.1%, 3
significant probes and log2 ratios >1. Differentially expressed
transcrips from both comparisons were subjected to pathway
analysis and clusters with ≥ 3 genes were defined as an
independent group. Up-regulated genes are shown on the left side
in red and down-regulated genes are displayed on the right side in
blue. The total numbers of significantly up- or down-regulated
genes from both comparions are indicated in circles placed in the
centers of individual pie charts. All differentially expressed genes are
listed in Tables 2 and 3, respectively.
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In the first set of experiments, mRNA levels of genes
up-regulated by luteolin treatment were assessed (Fig.
3). Transcripts of Sulfirexodin 1 (Srxn1), Biliverdin
reductase B (Blvrb), Heme oxigenase 1 (Hmox1), and
Glutamate-cysteine ligase (Gclm) are components of the
cellular anti-oxidant response [41-43] and were all
induced by luteolin treatment (Fig. 3A-D). We could
further validate increased levels of Lysophosphatidylcho-
line acyltransferase (Lpcat1), Ring finger protein 145
(Rnf145), Cd36 antigen, Kinase insert domain receptor
(Kdr, alias Vegfr2), and Cd83 antigen. Lpcat1 catalyzes
the inactivation of inflammatory lipids [44], whereas
Cd36 and Kdr are surface receptors required for phago-
cytic uptake and chemotactic migration, respectively
[45,46]. The function of Rnf145 is currently unknown.
In the next set of qRT-PCR experiments, down-regu-
lated transcripts involved in pro-inflammatory activation
and acute phase response were analyzed. Complement
factor C3 (C3), Complement factor b (Cfb), Secreted
leukocyte peptidase inhibitor (Slpi), and the pro-inflam-
matory Guanylate binding proteins 2 (Gbp2) and Gbp3
[47] showed diminished mRNA levels in luteolin-treated
samples (Fig. 4A-D). The same tendency was seen in
the newly identified microRNA miR-147, which is
involved in toll-like receptor signaling [48], the acute
phase gene Haptoglobin (Hp), the stress-related gene
Nuclear protein 1 (Nupr1, alias p8) [49], and Cystatin 7
(Cst7) (Fig. 4F-I).
As third group of genes validated by qRT-PCR, four
luteolin-repressed genes related to apoptosis and micro-
glial shape formation were studied (Fig. 5A-D). The
apoptotic mediators DNA-damage inducible transcript 3
(Ddit3, alias Chop, Gadd153) and Tribbles homolog 3
[50,51] were down-regulated by luteolin in non-activated
as well as LPS-activated microglia (Fig. 5A, B), indicat-
ing anti-apoptotic protection mechanisms elicited by
luteolin. In line with these findings, we also observed
reduced expression of the Macrophage receptor with
collagenous structure (Marco) and Lipocalin 2 (Lcn2),
two molecules with dual roles in apoptosis and de-rami-
fication of activated microglia [52,53].
Luteolin changes microglial morphology and inhibits NO
secretion
To assess whether the particular gene expression pro-
files measured in luteolin-stimulated microglia translate
into detectable functional properties, phenotypic charac-
terization was performed. The general activation state
and morphological phenotype of microglia is particularly
reflected by their cell shape and cytoskeletal organiza-
tion. To detected morphological changes and for visuali-
zation of filopodia we performed phalloidin staining.
Conventional BV-2 microglia cultures were low level
activated cells with a flat shape and some filopodia (Fig.
6A). Culture of BV-2 cells in the presence of luteolin
lead to considerable ramification and formation of long
protrusions (Fig. 6B), indicating induction of a surveil-
lance state. LPS-activation of BV-2 cells caused
Table 2 Differentially expressed transcripts after 24 h stimulation of BV-2 cells with 50 μM luteolin
Nr ID Symbol Gene Name FC* Cov
UP-REGULATED
1 74315 Rnf145 Ring finger protein 145 2.87 11
2 76650 Srxn1 Sulfiredoxin 1 homolog 2.38 5
3 19252 Dusp1 Dual specificity phosphatase 1 2.35 10
4 12267 C3ar1 Complement component 3a receptor 1 2.30 22
5 12491 Cd36 CD36 antigen 2.28 10
6 12475 Cd14 CD14 antigen 2.25 10
7 233016 Blvrb Biliverdin reductase B 2.22 9
8 15368 Hmox1 Heme oxygenase 1 2.17 10
9 210992 Lpcat1 Lysophosphatidylcholine acyltransferase 1 2.13 11
DOWN-REGULATED
1 13198 Ddit3 DNA-damage inducible transcript 3 -5.21 11
2 12862 Cox6a2 Cytochrome c oxidase, subunit VI a, polypeptide 2 -2.89 9
3 228775 Trib3 Tribbles homolog 3 -2.62 22
4 56312 Nupr1 Nuclear protein 1 -2.36 15
5 13011 Cst7 Cystatin F -2.19 9
6 223920 Soat2 Sterol O-acyltransferase 2 -2.16 8
7 16149 Cd74 CD74 antigen -2.10 8
8 17064 Cd93 CD93 antigen -2.08 11
9 213002 Ifitm6 Interferon induced transmembrane protein 6 -2.06 8
Significance analysis of triplicate microarrays was performed with a false discovery rate of 0.1% and a minimum probe coverage of 3. ID, Entrez Gene ID;F C :F o l d
change; Cov: probe coverage; * validated by Taqman realtime RT-PCR
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Page 7 of 16Table 3 Differentially expressed transcripts after 24 h stimulation with 50 μM luteolin + 50 ng/ml LPS versus
50 ng/ml LPS
Nr ID Symbol Gene Name FC* Cov
UP-REGULATED
1 74315 Rnf145 Ring finger protein 145 3.27 11
2 210992 Lpcat1 Lysophosphatidylcholine acyltransferase 1 2.55 11
3 12522 Cd83 CD83 antigen 2.51 11
4 14630 Gclm Glutamate-cysteine ligase, modifier subunit 2.46 10
5 16889 Lipa Lysosomal acid lipase A 2.31 6
6 56336 B4galt5 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 2.30 8
7 14950 H13 Histocompatibility 13 2.30 7
8 14104 Fasn Fatty acid synthase 2.28 4
9 12125 Bcl2l11 BCL2-like 11 2.16 14
10 16542 Kdr Kinase insert domain protein receptor 2.16 9
11 216345 Ccdc131 Coiled-coil domain containing 131 2.11 7
DOWN-REGULATED
1 66141 Ifitm3 Interferon induced transmembrane protein 3 -13.74 9
2 433470 AA467197 Expressed sequence AA467197, miR-147 -9.32 9
3 16819 Lcn2 Lipocalin 2 -6.87 10
4 14469 Gbp2 Guanylate binding protein 2 -6.41 16
5 14962 Cfb Complement factor B -5.94 8
6 13198 Ddit3 DNA-damage inducible transcript 3 -5.58 11
7 16181 Il1rn Interleukin 1 receptor antagonist -5.28 33
8 55932 Gbp3 Guanylate binding protein 3 -4.72 10
9 56312 Nupr1 Nuclear protein 1 -4.35 15
10 75345 Slamf7 SLAM family member 7 -4.14 9
11 20210 Saa3 Serum amyloid A 3 -3.78 7
12 17386 Mmp13 Matrix metallopeptidase 13 -3.63 11
13 15439 Hp Haptoglobin -3.56 11
14 17167 Marco Macrophage receptor with collagenous structure -3.34 8
15 12266 C3 Complement component 3 -3.29 6
16 12870 Cp Ceruloplasmin -3.05 5
17 13011 Cst7 Cystatin F -3.03 9
18 23882 Gadd45g Growth arrest and DNA-damage-inducible 45 gamma -2.95 11
19 242341 Atp6v0d2 ATPase, H+ transporting, lysosomal V0 subunit D2 -2.81 13
20 68774 Ms4a6d Membrane-spanning 4-domains, subfamily A, member 6D -2.75 19
21 83673 Snhg1 Small nucleolar RNA host gene 1 -2.75 24
22 12494 Cd38 CD38 antigen -2.73 6
23 19655 Rbmx RNA binding motif protein, X chromosome -2.73 11
24 56405 Dusp14 Dual specificity phosphatase 14 -2.68 10
25 213002 Ifitm6 Interferon induced transmembrane protein 6 -2.57 8
26 12517 Cd72 CD72 antigen -2.55 9
27 14129 Fcgr1 Fc receptor, IgG, high affinity I -2.55 11
28 14130 Fcgr2b Fc receptor, IgG, low affinity IIb -2.48 27
29 231532 Arhgap24 Rho GTPase activating protein 24 -2.46 8
30 29818 Hspb7 Heat shock protein family, member 7 (cardiovascular) -2.45 5
31 17476 Mpeg1 Macrophage expressed gene 1 -2.43 6
32 66222 Serpinb1a Serine peptidase inhibitor, clade B, member 1a -2.41 10
33 78771 Mctp1 Multiple C2 domains, transmembrane 1 -2.39 8
34 20568 Slpi Secretory leukocyte peptidase inhibitor -2.39 9
35 12507 Cd5 CD5 antigen -2.35 9
36 50778 Rgs1 Regulator of G-protein signaling 1 -2.35 11
37 21897 Tlr1 Toll-like receptor 1 -2.20 5
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Page 8 of 1638 16149 Cd74 CD74 antigen -2.17 5
39 73167 Arhgap8 Rho GTPase activating protein 8 -2.13 8
40 15064 Mr1 Major histocompatibility complex, class I-related -2.06 7
41 347722 Centg2 Centaurin, gamma 2 -2.04 11
42 98365 Slamf9 SLAM family member 9 -2.04 8
43 72999 Insig2 Insulin induced gene 2 -2.00 8
Significance analysis of triplicate microarrays was performed with a false discovery rate of 0.1% and a minimum probe coverage of 3. ID, Entrez Gene ID;F C :F o l d
change; Cov: probe coverage; * validated by Taqman realtime RT-PCR
Figure 3 Luteolin induces anti-oxidant, anti-inflammtory, and survival pathways. Real-time qRT-PCR validation of transcripts in BV-2
microglia stimulated with 50 μM luteolin, 50 ng/ml LPS, or 50 μM luteolin + 50 ng/ml LPS. Relative mRNA levels were quantified for (A)
Sulfiredoxin 1 (Srxn1), (B) Biliverdin reductase b (Blvrb), (C) Heme oxigenase 1 (Hmox1), (D) Glutamate-cysteine ligase modifier subunit (Gclm), (E)
Lysophosphatidylcholine acyltransferase 1 (Lpcat1), (F) Ring finger protein 145 (Rnf145), (G) Cd36 antigen (Cd36), (H) Kinase insert domain protein
receptor (Kdr), and (I) Cd83 antigen (Cd83). Expression was normalized to the control gene Gusb and mRNA levels (+/- SEM) are graphed relative
to mock-treated control cells. Results are calculated from three independent experiments performed in triplicate measurements. * p ≤ 0.05, ** p
≤ 0.01, *** p ≤ 0.001 for luteolin vs. control and luteolin + LPS vs. LPS, respectively.
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Page 9 of 16Figure 4 Luteolin inhibits pro-inflammtory and stress-related pathways. Real-time qRT-PCR validation of transcripts in BV-2 microglia
stimulated with 50 μM luteolin, 50 ng/ml LPS, or 50 μM luteolin + 50 ng/ml LPS. Relative mRNA levels were quantified for (A) Complement
component 3 (C3), (B) Complement factor B (Cfb), (C) Serine leukocyte peptidase inhibitor (Spli), (D) Guanylate binding protein 2 (Gnbp2), (E)
Guanylate binding protein 3 (Gnbp3), (F) micro RNA 147 (miR-147), (G) Haptoglobin (Hp), (H) Nuclear protein 1 (Nupr1), and (I) Cystatin F (Cst7).
Expression was normalized to the control gene Gusb and mRNA levels (+/- SEM) are graphed relative to mock-treated control cells. Results are
calculated from three independent experiments performed in triplicate measurements. * p ≤ 0.05, ** p ≤ 0.01 for luteolin vs. control and luteolin
+ LPS vs. LPS, respectively.
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Page 10 of 16formation of a round cell shape with retracted filopodia
(Fig. 6C). In contrast, co-incubation of LPS-treated cells
with luteolin sustained the ramified microglial morphol-
ogy (Fig. 6D). A similar effect was seen in primary
mouse microglia, where luteolin increased the length of
filopodia in non-activated cells (Fig. 6E, F) and caused
flatening and ramification of LPS-treated cells (Fig. 6G,
H). To test the direct effect of luteolin on microglial
secretion of toxic metabolites, NO levels were deter-
mined in the supernatant of BV-2 cells. Treatment of
BV-2 cells with luteolin alone did not result in increased
NO concentrations (Fig. 6I), whereas stimulation with
LPS markedly increased secreted NO levels. Co-incuba-
tion of LPS-activated cells with luteolin nearly comple-
tely abolished NO secretion (Fig. 6I). These data
indicate that luteolin favors the ramified surveillance
state of microglia and effectively inhibits cytotoxic NO
formation. Kim et al. previously reported that luteolin
triggered a blockade of NO secretion in LPS-stimulated
BV-2 microglia, which was mediated by inhibition of
inducible NO synthase (iNos) protein expression [54].
To indenpendently verify these data by qRT-PCR, we
analyzed iNos mRNA levels in BV-2 cells treated with
luteolin, LPS, or both simultaneously. LPS caused a
more than 40-fold increase in iNos transcripts and
luteolin co-treatment significantly reduced iNos levels
more than 2-fold. Thus, our expression data corroborate
t h ef i n d i n g sb yK i met al. and provide a reasonable
explanation for reduced NO secretion levels.
To test the hypothesis that luteolin leads to decreased
microglial neurotoxicity, a culture system of 661W
photoreceptor cells with conditioned medium (CM)
from BV-2 cells or primary microglia was established.
661W, a retina-derived cell line [55], represents a valu-
able model to study microglial neurotoxicity in the spe-
cial context of retinal degeneration [36]. 661W cells
were incubated for 24 h with culture supernatants from
unstimulated, luteolin-, LPS- or LPS + luteolin-treated
cells and 661W photoreceptor cell morphology was
assessed by phase contrast microscopy. 661W cells in
their own medium grew confluent after 24 h and the
presence of CM from control- or luteolin-treated BV-2
cells did not affect cell morphology (Fig. 7A, B). As
described previously [56], confluent 661W cells flattened
out and often multiple cells were connected to each
other through their projected extensions (Fig. 7A, B). In
contrast, 661W cells co-incubated with LPS-stimulated
BV-2 supernatant appeared elongated and smaller, lead-
ing to prominent cell-free areas present in the culture
(Fig. 7C). When adding CM from LPS + luteolin-stimu-
lated BV-2 cells, nearly normal cell characteristics were
retained (Fig. 7D). Similar morphological changes of
661W cells were observed when cultured in the pre-
sence of primary microglia CM (Fig. 7E-H). Direct incu-
bation of photoreceptor cells with LPS, luteolin, or both
had no effects on cell morphology (data not shown),
indicating that the observed changes in 661W cell
growth arise from secreted microglial compounds.
To correlate the microscopic findings with functional
data, we next studied the influence of microglia-secreted
products on caspase-related apoptotic signaling in the
neuronal cell model. 661W cells cultured in the pre-
sence of CM from LPS-stimulated BV-2 cells displayed
a strong induction of caspase 3/7 activity (Fig. 7I).
When CM from microglia co-treated with LPS + luteo-
lin was used, 661W apoptosis was still present but was
Figure 5 Luteolin inhibits apoptosis-related pathways and
reduces de-ramification genes. Real-time qRT-PCR validation of
transcripts in BV-2 microglia stimulated with 50 μM luteolin, 50 ng/
ml LPS, or 50 μM luteolin + 50 ng/ml LPS. Relative mRNA levels
were quantified for (A) DNA-damage inducible transcript 3 (Ddit3),
(B) Tribbles homolog 3 (Trib3), (C) Macrophage receptor with
collagenous structure (Marco), and (D) lipocalin 2 (Lcn2). Expression
was normalized to the control gene Gusb and mRNA levels (+/-
SEM) are graphed relative to mock-treated control cells. Results are
calculated from three independent experiments performed in
triplicate measurements. * p ≤ 0.05 for luteolin vs. control and
luteolin + LPS vs. LPS, respectively.
Dirscherl et al. Journal of Neuroinflammation 2010, 7:3
http://www.jneuroinflammation.com/content/7/1/3
Page 11 of 16Figure 7 Luteolin inhibits microglial neurotoxicity on photoreceptors. Phase contrast micrographs showing morphological changes of
661W photoreceptor cultures treated with conditioned media from BV-2 cells (A-D) or primary brain microglia (E-H). The supernatant from
control-stimulated (A, E), 50 μM luteolin-treated (B, F), 50 ng/ml LPS-treated (C, G), or 50 μM luteolin + 50 ng/ml LPS-treated cells (D, H) was
added to 661W photoreceptor cells, respectively. The micrographs shown are from one representative experiment out of three independent
experiments with the same tendencies. Scale bar, 50 μM. (I) Apoptosis-related caspase 3/7 activation in 661W photoreceptor cells incubated with
conditioned media from control-stimulated, 50 μM luteolin-treated, 50 ng/ml LPS-treated, or 50 μM luteolin + 50 ng/ml LPS-treated BV-2 cells.
Results are calculated from two independent experiments performed in triplicate measurements. ** p ≤ 0.01, * p ≤ 0.05 for LPS vs. control and
luteolin + LPS vs. LPS, respectively.
Figure 6 Luteolin promotes ramification of microglia and inhibits NO-synthesis. Effects of luteolin, LPS and Luteolin + LPS on BV-2 (A-D)
and primary brain microglia (E-H) cell morphology and actin cytoskeleton. Phallodin-TRITC-staining of F-actin bundles and DAPI costaining
reveals that 24 h treatment with 50 μM luteolin in non-activated (B, F) or LPS-activated microglia (D, H) supports ramification. (I) NO release from
BV-2 cells treated for 24 h with 50 μM luteolin, 50 ng/ml LPS, or LPS + luteolin. The micrographs and data shown are from one representative
experiment out of three independent experiments with the same tendencies. Scale bar, 50 μM. (J) Real-time qRT-PCR analysis of iNos transcripts
in BV-2 microglia stimulated with 50 μM luteolin, 50 ng/ml LPS, or 50 μM luteolin + 50 ng/ml LPS. Expression was normalized to the control
gene Gusb and mRNA levels (+/- SEM) are graphed relative to mock-treated control cells. Results are calculated from two independent
experiments performed in triplicate measurements. *** p ≤ 0.001, ** p ≤ 0.01 for LPS vs. control and luteolin + LPS vs. LPS, respectively.
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Page 12 of 16significantly diminished (Fig. 7I). Culture media from
BV-2 cells kept in the presence of luteolin alone had no
effect on 661W apoptosis. These findings implicate that
luteolin either stimulates microglia to produce less pro-
apoptotic substances or actively promotes the release of
survival signals.
Discussion
Like other plant-derived flavonoids, luteolin has a variety
of biological activities including well-known anti-muta-
genic and anti-tumorigenic properties [57]. Moreover,
this flavone possesses direct anti-oxidant activity, which
is attributed to structural features of all flavonoids, which
favor scavenging of reactive oxygen and nitrogen species
[58]. Although the anti-oxidant and anti-inflammatory
activities of luteolin may be also useful in the treatment
of many chronic inflammatory diseases including neuro-
degeneration, only little information is available about
luteolin-mediated transcriptional mechanisms or molecu-
lar targets in microglia [59].
We have therefore performed the first genome-wide
study of luteolin-mediated transcriptional effects in
microglia. To our surprise, luteolin treatment did not
only change expression levels of a few transcripts but had
a broad and strong impact on the transcriptome of rest-
ing and particularly of LPS-activated microglia. The
microarray dataset and the qRT-PCR validations revealed
several luteolin-regulated pathways. Luteolin caused
simultaneous up-regulation of four important anti-oxi-
dant enzymes Srxn1, Blvrb, Gclm, and Hmox1. These
data are consistent with earlier findings demonstrating
increased Hmox1 transcription in RAW264.7 macro-
phages after luteolin treatment [60]. Stimulation with the
flavonoid induced binding of the transcription factor NF-
E2-related factor 2 (Nrf2) to anti-oxidant response ele-
ments (ARE) in the Hmox1 promoter region [60]. Luteo-
lin is a potent activator of Nrf2 [61] and the majority of
anti-oxidant enzymes contain ARE in their regulatory
regions, including Srxn1 [62]. Moreover, mouse embryo-
nic fibroblasts derived from Nrf2 -/- mice showed signifi-
cantly lower Blvrb and Gclm mRNA levels upon Diquat
induction [63]. Therefore, we speculate that increased
microglial expression of Srxn1, Blvrb, and Gclm is also
mediated by activation of Nrf2. This hypothesis is further
corroborated by the protective functions of Nrf2 in sev-
eral microglia-related neurodegenerative disorders [64].
Luteolin significantly enhanced mRNA synthesis of
five other genes involved in different biological path-
ways. Lpcat1 is a lysophospholipid acyltransferase impli-
cated in anti-inflammatory responses by converting lyso-
platelet activation factor (lyso-PAF) to PAF and lyso-
phosphatidylcholine (lyso-PC) to PC [65]. LPC exerts
considerable neuro-inflammatory reactivity in the brain
and inhibition of LPC signaling in astrocytes and
microglia confers neuroprotection [66]. Lpcat1 is also
highly expressed in the retina [44], indicating that luteo-
lin-induced Lpact1 levels could lead to diminished LPC
levels in retinal microglia. Rnf145 was also up-regulated
by luteolin but the function of this protein remains to
be determined. Cd36 and Kdr (alias Vegfr2) were also
significantly induced by luteolin in non-activated as well
as activated microglia. The pattern recognition receptor
Cd36 signals to the actin cytoskeleton and regulates
microglial migration and phagocytosis [67], whereas Kdr
is involved in the chemotactic response of microglia
[46]. We thus speculate that luteolin-mediated expres-
sion of both genes could result in increased phagocytic
responses of microglia without inducing inflammation.
Several reports have demonstrated that luteolin inhi-
bits pro-inflammatory cytokine expression in various
cell types by blocking NFkB (reviewed in [28]). Our
microarray data confirmed these findings and revealed
further NFkB target genes including the recently discov-
ered microRNA miR-147 [48]. Recently, Jang et al.
showed that luteolin reduced Il6 production mainly by
inhibiting JNK signaling and AP1 activation [34]. Luteo-
lin did not affect IkB-a degradation or NFkB DNA
binding in brain microglia, implicating that luteolin-
mediated effects in microglia are not solely dependent
on NFkB blockade [34]. In line with this notion, our
luteolin-regulated expression profiles identified several
genes with NFkB-independent promoter control. Like-
wise, luteolin down-regulated complement factor 3,
which is regulated by AP1 [68] and blocked expression
of Slpi, which is a target of interferon regulatory factor
1 (IRF1) [69]. Luteolin also diminished mRNA levels of
the pro-inflammatory GTPase Gbp2 and the acute
phase protein Haptoglobin, which are both regulated by
signal transducers and activators of transcription
(STATs) [70,71]. These data clearly show that luteolin
dampens microglia activation by interfering with several
divergent signaling pathways.
The luteolin-regulated differential expression patterns
also revealed genes involved in microglial apoptosis and
ramification. Microglia are more susceptible than
macrophages to apoptosis [72] and recent evidence indi-
cates that microglial apoptosis and senescence may pre-
cede neurodegeneration [73]. Ddit 3 and Trib3, which
were both induced by LPS and suppressed by luteolin,
support stress and NO-mediated apoptosis [50,51]. We
therefore hypothesize that luteolin could promote the
survival of activated and stressed microglia in an envir-
onment of early neurodegeneration. Our expression data
also revealed the unexpected finding that luteolin down-
regulated Lcn2 and Marco, two molecules involved in
microglial ramification and formation of filopodia. Lee
et al. demonstrated that stable expression of Lcn in BV-
2 microglia, the same cell line we used in our
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processes [52]. In line with this, over-expression of the
scavenger receptor Marco in dendritic cells caused
rounding of cells and down-regulated antigen uptake
[53]. Thus, we hypothesized that the observed changes
in mRNA levels of both genes might also translate into
different morphological characters.
The morphological and functional assays fully sup-
ported the implications from gene expression profiles
and revealed a direct effect of luteolin on the microglial
phenotype. Luteolin stimulated the formation of filopo-
dia and caused ramification of BV-2 cells and primary
m i c r o g l i ae v e ni nt h es e t t i n g of strong LPS activation.
Moreover, NO secretion was completely blocked in
LPS-activated microglia upon co-incubation with luteo-
lin. We studied the effects of conditioned media from
microglia on cultured photoreceptor-like 661W cells
and demonstrated that luteolin-treatment effectively
protected 661W cells from LPS-induced microglial toxi-
city. Since NO and other reactive oxygen species are the
major radicals secreted from microglia, we speculate
that luteolin directly inhibits the secretion of these cyto-
toxic radicals. Our hypothesis is corroborated by recent
data demonstrating that luteolin concentration-depen-
dently attenuated LPS-induced dopaminergic neuron
loss by blocking NO secretion from cultured rat micro-
glia [32].
Conclusions
We have shown that the flavonoid luteolin is a potent
modulator of microglial activation, cell shape, and effec-
tor functions. Luteolin induced global changes in the
transcriptome of resting or LPS-activated microglia lead-
ing to a polarized M2-like phenotype with anti-inflam-
matory and neuroprotective characteristics. Luteolin’s
mechanisms of action appear to target several indepen-
dent pathways independent of NFkB. Our results pro-
v i d eab a s i st od e v e l o pi m m u n o - m o d u l a t o r ya n d
neuroprotective therapies for the treatment of neurode-
generative disoders.
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